Moleculin Biotech, Inc. (MBRX) Financials
MBRX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 23.4 million | 8.2 million |
| Dec. 31, 2025 | 22.1 million | 7.1 million |
| Sept. 30, 2025 | 20.4 million | 47.3 million |
| June 30, 2025 | 21.6 million | 28.8 million |
MBRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -6.1 million | 380000 |
| Dec. 31, 2025 | -5.4 million | 459000 |
| Sept. 30, 2025 | -7.2 million | 303000 |
| June 30, 2025 | -5.6 million | 417000 |
MBRX Net Income
No data available :(
MBRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 10.3 million | 185000 | - |
| Dec. 31, 2025 | 8.9 million | - | 222000 |
| Sept. 30, 2025 | 6.7 million | - | 258000 |
| June 30, 2025 | 7.6 million | - | 292000 |
MBRX Shares Outstanding
MBRX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | - | 5.4 million | 2.5 million | - |
| Dec. 31, 2025 | - | 5.1 million | 2.4 million | - |
| Sept. 30, 2025 | - | 3.7 million | 2.1 million | - |
| June 30, 2025 | - | 3.6 million | 2.1 million | - |
MBRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | - | 8000 |
| Dec. 31, 2025 | - | 9000 |
| Sept. 30, 2025 | - | 21000 |
| June 30, 2025 | - | 29000 |
MBRX
Price: $2.12
52 week price:
Earnings Per Share: -28.42 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 14187
Ebitda: -2.9 millionMarket Capitalization: 14.1 million